First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

Sikander Ailawadhi, Yifan Zhai, Asher Chanan‐Khan et al.|Journal of Clinical Oncology|2021

Cited by 25